• Consider Nvidia (NVDA) around $173–$174 after its sharp selloff; the speaker viewed the dip as attractive, but weigh volatility, competition, and geopolitical risks.
• Praxis Precision Medicines (PRAX) was called a good investment, though crowded fund ownership raises caution; no price target or timeline was provided.
• The speaker was bearish on Sellas Life Sciences (SLS), expecting its Phase 3 trial to fail; treat this as a high-risk, event-driven stock rather than a long-term holding.
• Avoid treating brief comments on other stocks as trade signals: the discussion provided little actionable support beyond these views.

Nvidia (NVDA)

• The speaker called Nvidia attractive around $173–$174 after the stock fell 7%–9%. It later recovered, at one point down about 4%.
• The selloff was discussed alongside a personal scandal involving CEO Jensen Huang and concerns about potential Chinese government targeting. The speaker also noted that AMD and Google gained as Nvidia fell.
• The speaker said demand remained good after earnings season and argued that Chinese companies have reason to buy GPUs. A historical comparison suggested that a drop of this size was not unusual for Nvidia, though the DeepSeek news had once caused a much worse one-hour decline.

Takeaways

• The transcript’s clearest bullish view was that Nvidia looked attractive at the quoted price, with the speaker treating the sharp move as potentially less significant than it appeared.
• Keep in mind the risks raised in the discussion: sharp price swings, competition, and geopolitical concerns. The transcript did not give a price target or investment timeline.

AMD (AMD) and Alphabet / Google (GOOGL)

• Both stocks gained while Nvidia fell. No specific valuation, price target, or detailed investment case was provided for either.
• The speaker said he would not short Google, but also remarked that Google could face a “weird time,” without explaining the concern in detail.

Takeaways

• The transcript offers little basis for a directional trade in either stock. Treat the price moves as market context, not as a standalone investment thesis.

Spruce Biosciences (SPRB)

• The company reported quarterly results and plans to split off a second asset. The speaker viewed the separation positively, noting that many investors may not have known the company had another asset.
• The stock’s moves were described as volatile and its trading as very thin: it was down as much as about 14%, later around 3% lower, with low trading volume.
• The speaker raised possible concerns about the company’s cash burn and said it may need to raise more capital to support a launch. He also speculated that it might be raising more than necessary. A potential priority review voucher (PRV) was mentioned in connection with approval.

Takeaways

• The asset split may make the company’s pipeline easier to assess, but the transcript does not establish the value of either asset.
• Low liquidity can exaggerate price moves. Consider the cash needs and financing risk before interpreting a volatile trading day as a change in the company’s prospects.

Sellas Life Sciences (SLS)

• The speaker said he thought the company’s Phase 3 trial would fail, calling the situation painful. The stock was mentioned as being down about 5% at one point.

Takeaways

• The discussion was clearly bearish on the trial outcome. For a company whose investment case depends on a clinical result, the trial outcome is a major risk; the transcript provided no further evidence or timeline.

Zura Bio (ZURA)

• The speaker said the drug “doesn’t work” and expressed no interest in the stock. Zura was also mentioned among biotech fund holdings, but no positive rationale for those holdings was given.

Takeaways

• The speaker’s view was strongly negative. The transcript gives no supporting trial details, so it is not enough on its own to assess the drug or the company independently.

Kodiak Sciences (KOD)

• The speaker said Kodiak’s drug was not attractive, without giving supporting details or a price view.
• Kodiak also appeared among the biotech holdings discussed in several fund portfolios.

Takeaways

• The speaker was negative on the drug, but the transcript did not explain why. Fund ownership alone should not be taken as evidence of a positive investment case.

Schrodinger (SDGR)

• The speaker said he had never been bullish on Schrodinger, while acknowledging that it has a software business.

Takeaways

• The transcript conveys a skeptical view, but does not assess the software business or explain the valuation. No specific recommendation or price target was given.

Revolution Medicines (RVMD)

• The speaker said the company had received an approval previously and reported that its first-quarter revenue was “quite good.” He added that the company would be fine.
• Revolution Medicines was also listed as a large holding in several biotech-focused portfolios.

Takeaways

• The comments were broadly positive, particularly about reported revenue, but the transcript did not specify the product, approval, valuation, or future expectations.

Praxis Precision Medicines (PRAX)

• The speaker called Praxis a “really good investment” and said the stock appeared attractive, while noting that it seemed crowded because many funds held it.
• It was listed among holdings of several biotech investment firms.

Takeaways

• The speaker was positive, but also flagged crowded ownership. The transcript did not provide a price target or explain the underlying clinical or commercial case.

Gilead Sciences (GILD)

• The speaker described Gilead as an interesting company and said he thought it was cheap, without giving a valuation or discussing specific products.

Takeaways

• This was a brief bullish valuation comment, not a complete investment thesis. The transcript offers no price target or explanation of what would make the stock re-rate.

Amgen (AMGN)

• The speaker called Amgen “very pricey” at about $456 and cited an enterprise value of roughly $300 billion.
• He pointed to concerns about the age of some of the company’s products: Prolia was described as facing biosimilar competition, while Repatha and Evenity were said to be growing around 40%.
• The speaker suggested Repatha could reach $6 billion in sales the following year and potentially $10 billion later, while discussing roughly ten more years of growth. Those figures were the speaker’s estimates, not a formal company forecast.

Takeaways

• The discussion presents a mixed picture: a high valuation and aging products on one side, strong growth in Repatha and Evenity on the other.
• The transcript specifically raises biosimilar competition as a risk for Prolia. It does not provide enough detail to assess the stated sales estimates or the valuation.

Other Biotech Companies and Fund Holdings

• The speaker discussed portfolio holdings across several funds, including Abivax, Roivant, Madrigal Pharmaceuticals, Acadia Pharmaceuticals, Insmed, Erasca, Edgewise Therapeutics, United Therapeutics, Belite Bio, Argenx, PTC Therapeutics, CG Oncology, Arrowhead Pharmaceuticals, Rhythm Pharmaceuticals, and Revolution Medicines.
• These names were presented mainly as examples of what biotech-focused funds own. The speaker noted that biotech companies often need to raise money and that drug development can take years.
• Aervant was mentioned as having a setback, and Acadia was described as having an unclear recent move. The transcript did not provide enough context to confidently identify or assess every company in the fund lists.

Takeaways

• Fund holdings can be useful for generating research ideas, but the transcript did not establish that these holdings were recommendations.
• The speaker explicitly emphasized biotech’s long development timelines and recurring financing needs. Those factors can make clinical-stage companies especially sensitive to trial results and capital availability.

Akamai Technologies (AKAM)

• Akamai was mentioned as being down about 6%, but no reason for the move or company-specific outlook was discussed.

Takeaways

• The transcript gives no investment thesis for Akamai. The price move alone does not provide a basis for a trade.

Cloudflare (NET)

• The speaker said Cloudflare had been very successful and praised its management team, while acknowledging that he had not recently reviewed the company’s numbers and did not know enough about its competition.

Takeaways

• The tone was favorable, but the speaker’s caveats are important: the transcript does not provide current financial analysis or a view on valuation and competition.

Chegg (CHGG)

• The speaker said he thought Chegg was “dead,” expressing a bearish view without further explanation.

Takeaways

• This was a blunt negative opinion, but no supporting business or financial details were offered.

Marvell Technology (MRVL)

• The speaker described a Marvell acquisition as “very dilutive.”

Takeaways

• The comment flags potential dilution from the acquisition, but the transcript does not identify the deal or quantify its impact. Assessing the concern would require details of the transaction and expected benefits.

Asian Stocks and Markets

• The speaker gave a brief market recap: Kyocera was down about 3%, Advantest down 1%, SoftBank down 4%, while Tokyo Electron and Lasertec were up about 3% and 1%, respectively. Toyota and Nintendo were each up about 5%.
• SoftBank was described as closely tied to OpenAI. No company-specific investment case was offered for the other stocks.

Takeaways

• These were market snapshots, not recommendations. The transcript did not explain the drivers of the moves or provide price targets.

Anthropic and Hyperliquid

• Anthropic was discussed in the context of a possible valuation, but the figure and the speaker’s unfinished reaction were too unclear to establish a meaningful valuation view.
• Hyperliquid was mentioned in a question about a decentralized stock-trading platform. The speaker asked what that meant but did not provide an investment opinion or discuss a token.

Takeaways

• The transcript does not provide a clear investment case for either opportunity. No specific price, valuation conclusion, or recommendation can be drawn from these comments.